HDAC8: A multifaceted target for therapeutic interventions

  • A. C
  • I. O
  • O. W
  • et al.
N/ACitations
Citations of this article
1Readers
Mendeley users who have this article in their library.

Abstract

Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections. It is a structurally well-characterized enzyme that also deacetylates nonhistone proteins. In cancer, HDAC8 is a major 'epigenetic player' that is linked to deregulated expression or interaction with transcription factors critical to tumorigenesis. In the parasite Schistosoma mansoni and in viral infections, HDAC8 is a novel target to subdue infection. The current challenge remains in the development of potent selective inhibitors that would specifically target HDAC8 with fewer adverse effects compared with pan-HDAC inhibitors. Here, we review HDAC8 as a drug target and discuss inhibitors with respect to their structural features and therapeutic interventions. Copyright © 2015 The Authors. Published by Elsevier Ltd.

Author supplied keywords

Cite

CITATION STYLE

APA

A., C., I., O., O., W., G., O., W., S., C., R., & R.J., P. (2015). HDAC8: A multifaceted target for therapeutic interventions. Trends in Pharmacological Sciences. M. Jung, Institute of Pharmaceutical Sciences, Albert-Ludwigs-Universitat Freiburg, Freiburg, Germany. E-mail: manfred.jung@pharmazie.uni-freiburg.de: Elsevier Ltd. Retrieved from http://www.elsevier.com/locate/tips

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free